# Microvision, Inc.: financial statements, quarterly MVIS · Nasdaq · CIK 65770 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/mvis.md) · [Financials](/companies/mvis/financials.md) · [Filings](/companies/mvis/filings.md) · [Insiders](/companies/mvis/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mvis/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [1.0](/filings/0001493152-24-044052.md) | [5.1 d](/filings/0001493152-26-008898.md) | [1.0](/filings/0001641172-25-009765.md) | [1.9](/filings/0001641172-25-022632.md) | [0.2](/filings/0001493152-25-021931.md) | [1.7 d](/filings/0001493152-26-008898.md) | [0.6](/filings/0001493152-26-023667.md) | [0.2](/filings/0001493152-26-036371.md) | [0.2](/filings/0001493152-25-021931.md) | [0.2 d](/filings/0001493152-26-008898.md) | [0.9](/filings/0001493152-26-023667.md) | [1.5](/filings/0001493152-26-036371.md) | | Cost of revenue | $m | [0.6](/filings/0001493152-24-044052.md) | [0.9 d](/filings/0001493152-26-008898.md) | [1.3](/filings/0001641172-25-009765.md) | [1.6](/filings/0001641172-25-022632.md) | [0.6](/filings/0001493152-25-021931.md) | [4.1 d](/filings/0001493152-26-008898.md) | [0.6](/filings/0001493152-26-023667.md) | [0.7](/filings/0001493152-26-036371.md) | [1.0](/filings/0001493152-25-021931.md) | [16.3 d](/filings/0001493152-26-008898.md) | [0.6](/filings/0001493152-26-023667.md) | [0.8](/filings/0001493152-26-036371.md) | | Gross profit | $m | [0.4](/filings/0001493152-24-044052.md) | [4.2 d](/filings/0001493152-26-008898.md) | [(0.3)](/filings/0001641172-25-009765.md) | [0.3](/filings/0001641172-25-022632.md) | [(0.4)](/filings/0001493152-25-021931.md) | [(2.5) d](/filings/0001493152-26-008898.md) | [0.0](/filings/0001493152-26-023667.md) | [(0.6)](/filings/0001493152-26-036371.md) | [(0.7)](/filings/0001493152-25-021931.md) | [(16.1) d](/filings/0001493152-26-008898.md) | [0.4](/filings/0001493152-26-023667.md) | [0.6](/filings/0001493152-26-036371.md) | | Research and development | $m | [15.6](/filings/0001493152-24-044052.md) | [14.6 d](/filings/0001493152-26-008898.md) | [17.3](/filings/0001641172-25-009765.md) | [14.2](/filings/0001641172-25-022632.md) | [8.7](/filings/0001493152-25-021931.md) | [8.8 d](/filings/0001493152-26-008898.md) | [7.4](/filings/0001493152-26-023667.md) | [7.7](/filings/0001493152-26-036371.md) | [8.0](/filings/0001493152-25-021931.md) | [8.7 d](/filings/0001493152-26-008898.md) | [14.4](/filings/0001493152-26-023667.md) | [15.7](/filings/0001493152-26-036371.md) | | Selling, general and administrative | $m | [8.7](/filings/0001493152-24-044052.md) | [9.5 d](/filings/0001493152-26-008898.md) | [9.1](/filings/0001641172-25-009765.md) | [7.7](/filings/0001641172-25-022632.md) | [6.6](/filings/0001493152-25-021931.md) | [5.9 d](/filings/0001493152-26-008898.md) | [6.7](/filings/0001493152-26-023667.md) | [6.4](/filings/0001493152-26-036371.md) | [4.0](/filings/0001493152-25-021931.md) | [3.2 d](/filings/0001493152-26-008898.md) | [9.5](/filings/0001493152-26-023667.md) | [9.2](/filings/0001493152-26-036371.md) | | Operating income | $m | [(23.9)](/filings/0001493152-24-044052.md) | [(19.9) d](/filings/0001493152-26-008898.md) | [(26.7)](/filings/0001641172-25-009765.md) | [(24.6)](/filings/0001641172-25-022632.md) | [(15.7)](/filings/0001493152-25-021931.md) | [(18.5) d](/filings/0001493152-26-008898.md) | [(14.0)](/filings/0001493152-26-023667.md) | [(14.7)](/filings/0001493152-26-036371.md) | [(12.7)](/filings/0001493152-25-021931.md) | [(41.4) d](/filings/0001493152-26-008898.md) | [(23.5)](/filings/0001493152-26-023667.md) | [(24.2)](/filings/0001493152-26-036371.md) | | Interest expense | $m | not reported | not reported | [0.0](/filings/0001641172-25-009765.md) | [0.0](/filings/0001641172-25-022632.md) | [0.0](/filings/0001493152-25-021931.md) | [4.4 d](/filings/0001493152-26-008898.md) | [7.3](/filings/0001493152-26-023667.md) | [2.2](/filings/0001493152-26-036371.md) | [2.2](/filings/0001493152-25-021931.md) | [0.0 d](/filings/0001493152-26-008898.md) | [2.8](/filings/0001493152-26-023667.md) | [5.5](/filings/0001493152-26-036371.md) | | Income tax | $m | [0.2](/filings/0001493152-24-044052.md) | [0.5 d](/filings/0001493152-26-008898.md) | [0.2](/filings/0001641172-25-009765.md) | [0.1](/filings/0001641172-25-022632.md) | [0.1](/filings/0001493152-25-021931.md) | [0.1 d](/filings/0001493152-26-008898.md) | [0.1](/filings/0001493152-26-023667.md) | [0.1](/filings/0001493152-26-036371.md) | [0.2](/filings/0001493152-25-021931.md) | [(0.4) d](/filings/0001493152-26-008898.md) | [0.2](/filings/0001493152-26-023667.md) | [0.2](/filings/0001493152-26-036371.md) | | Net income | $m | [(23.5)](/filings/0001493152-24-044052.md) | [(19.7) d](/filings/0001493152-26-008898.md) | [(26.3)](/filings/0001641172-25-009765.md) | [(23.9)](/filings/0001641172-25-022632.md) | [(15.5)](/filings/0001493152-25-021931.md) | [(31.2) d](/filings/0001493152-26-008898.md) | [(28.8)](/filings/0001493152-26-023667.md) | [(14.2)](/filings/0001493152-26-036371.md) | [(14.2)](/filings/0001493152-25-021931.md) | [(37.8) d](/filings/0001493152-26-008898.md) | [(25.3)](/filings/0001493152-26-023667.md) | [(36.9)](/filings/0001493152-26-036371.md) | | Diluted EPS | $ per share | [(0.12)](/filings/0001493152-24-044052.md) | not reported | [(0.13)](/filings/0001641172-25-009765.md) | [(0.11)](/filings/0001641172-25-022632.md) | [(0.07)](/filings/0001493152-25-021931.md) | not reported | [(0.12)](/filings/0001493152-26-023667.md) | [(0.84)](/filings/0001493152-26-036371.md) | [(0.05)](/filings/0001493152-25-021931.md) | not reported | [(0.08)](/filings/0001493152-26-023667.md) | [(1.66)](/filings/0001493152-26-036371.md) | | Basic EPS | $ per share | [(0.12)](/filings/0001493152-24-044052.md) | not reported | [(0.13)](/filings/0001641172-25-009765.md) | [(0.11)](/filings/0001641172-25-022632.md) | [(0.07)](/filings/0001493152-25-021931.md) | not reported | [(0.12)](/filings/0001493152-26-023667.md) | [(0.84)](/filings/0001493152-26-036371.md) | [(0.05)](/filings/0001493152-25-021931.md) | not reported | [(0.08)](/filings/0001493152-26-023667.md) | [(1.66)](/filings/0001493152-26-036371.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfGoodsAndServicesSold, us-gaap:CostOfRevenue - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpenseNonoperating, us-gaap:InterestExpense - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [49.4](/filings/0001493152-24-044052.md) | [45.2](/filings/0001493152-26-008898.md) | [44.3](/filings/0001641172-25-009765.md) | [26.7](/filings/0001641172-25-022632.md) | [16.5](/filings/0001493152-25-021931.md) | [54.5](/filings/0001493152-26-008898.md) | [51.9](/filings/0001493152-26-023667.md) | [74.1](/filings/0001493152-26-036371.md) | [72.8](/filings/0001493152-25-021931.md) | [32.4](/filings/0001493152-26-036371.md) | [46.1](/filings/0001493152-26-023667.md) | [27.2](/filings/0001493152-26-036371.md) | | Current assets | $m | [91.4](/filings/0001493152-23-040075.md) | [86.8](/filings/0001641172-25-000783.md) | [82.3](/filings/0001493152-24-018637.md) | [66.6](/filings/0001493152-24-030625.md) | [53.0](/filings/0001493152-24-044052.md) | [82.5](/filings/0001493152-26-008898.md) | [79.0](/filings/0001641172-25-009765.md) | [103](/filings/0001641172-25-022632.md) | [115](/filings/0001493152-25-021931.md) | [81.1](/filings/0001493152-26-036371.md) | [54.2](/filings/0001493152-26-023667.md) | [34.3](/filings/0001493152-26-036371.md) | | Total assets | $m | [136](/filings/0001493152-23-040075.md) | [130](/filings/0001641172-25-000783.md) | [124](/filings/0001493152-24-018637.md) | [103](/filings/0001493152-24-030625.md) | [88.3](/filings/0001493152-24-044052.md) | [121](/filings/0001493152-26-008898.md) | [117](/filings/0001641172-25-009765.md) | [141](/filings/0001641172-25-022632.md) | [151](/filings/0001493152-25-021931.md) | [103](/filings/0001493152-26-036371.md) | [110](/filings/0001493152-26-023667.md) | [88.6](/filings/0001493152-26-036371.md) | | Current liabilities | $m | [24.1](/filings/0001493152-23-040075.md) | [20.5](/filings/0001641172-25-000783.md) | [17.8](/filings/0001493152-24-018637.md) | [12.7](/filings/0001493152-24-030625.md) | [10.6](/filings/0001493152-24-044052.md) | [46.0](/filings/0001493152-26-008898.md) | [41.9](/filings/0001641172-25-009765.md) | [42.8](/filings/0001641172-25-022632.md) | [39.9](/filings/0001493152-25-021931.md) | [30.1](/filings/0001493152-26-036371.md) | [51.8](/filings/0001493152-26-023667.md) | [50.4](/filings/0001493152-26-036371.md) | | Total liabilities | $m | [37.7](/filings/0001493152-23-040075.md) | [33.8](/filings/0001641172-25-000783.md) | [30.4](/filings/0001493152-24-018637.md) | [24.7](/filings/0001493152-24-030625.md) | [22.4](/filings/0001493152-24-044052.md) | [72.4](/filings/0001493152-26-008898.md) | [63.5](/filings/0001641172-25-009765.md) | [63.5](/filings/0001641172-25-022632.md) | [60.1](/filings/0001493152-25-021931.md) | [47.6](/filings/0001493152-26-036371.md) | [70.7](/filings/0001493152-26-023667.md) | [68.0](/filings/0001493152-26-036371.md) | | Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | [33.0](/filings/0001493152-26-008898.md) | [30.1](/filings/0001641172-25-009765.md) | [32.3](/filings/0001641172-25-022632.md) | [29.0](/filings/0001493152-25-021931.md) | [19.2](/filings/0001493152-26-036371.md) | [32.1](/filings/0001493152-26-023667.md) | [24.6](/filings/0001493152-26-036371.md) | | Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Shareholders' equity | $m | [98.3](/filings/0001493152-24-044052.md) | [95.8](/filings/0001493152-26-008898.md) | [93.8](/filings/0001641172-25-022632.md) | [78.7](/filings/0001493152-25-021931.md) | [65.9](/filings/0001493152-25-021931.md) | [48.8](/filings/0001493152-26-036371.md) | [53.2](/filings/0001493152-26-036371.md) | [77.1](/filings/0001493152-26-036371.md) | [90.7](/filings/0001493152-25-021931.md) | [55.5](/filings/0001493152-26-036371.md) | [39.5](/filings/0001493152-26-036371.md) | [20.6](/filings/0001493152-26-036371.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebt - Current portion of debt: not reported - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [(20.4) d](/filings/0001493152-24-044052.md) | [(16.6) d](/filings/0001493152-26-008898.md) | [(20.8)](/filings/0001641172-25-009765.md) | [(18.6) d](/filings/0001641172-25-022632.md) | [(14.1) d](/filings/0001493152-25-021931.md) | [(15.1) d](/filings/0001493152-26-008898.md) | [(14.1)](/filings/0001493152-26-023667.md) | [(12.7) d](/filings/0001493152-26-036371.md) | [(16.5) d](/filings/0001493152-25-021931.md) | [(15.4) d](/filings/0001493152-26-008898.md) | [(16.4)](/filings/0001493152-26-023667.md) | [(19.1) d](/filings/0001493152-26-036371.md) | | Capital expenditure | $m | [0.5 d](/filings/0001493152-24-044052.md) | [(0.0) d](/filings/0001493152-26-008898.md) | [0.1](/filings/0001641172-25-009765.md) | [0.2 d](/filings/0001641172-25-022632.md) | [(0.0) d](/filings/0001493152-25-021931.md) | [0.1 d](/filings/0001493152-26-008898.md) | [0.1](/filings/0001493152-26-023667.md) | [0.2 d](/filings/0001493152-26-036371.md) | [0.1 d](/filings/0001493152-25-021931.md) | [0.2 d](/filings/0001493152-26-008898.md) | [0.1](/filings/0001493152-26-023667.md) | [0.3 d](/filings/0001493152-26-036371.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment ## Shares | Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [166](/filings/0001493152-23-040075.md) | [175](/filings/0001493152-24-018637.md) | [177](/filings/0001493152-24-030625.md) | [188](/filings/0001493152-24-044052.md) | [197](/filings/0001641172-25-009765.md) | [209](/filings/0001641172-25-022632.md) | [213](/filings/0001493152-25-021931.md) | [236](/filings/0001493152-26-023667.md) | [17.0](/filings/0001493152-26-036371.md) | [295](/filings/0001493152-25-021931.md) | [309](/filings/0001493152-26-023667.md) | [22.3](/filings/0001493152-26-036371.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 23,788,425 at 2026-08-03, from the cover of the [10-Q filed 2026-08-06](/filings/0001493152-26-036371.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:19 ET. No prices; not investment advice.